Email Updates

You are here

TDF2

Status
Completed
Phase
III
II
Principal Investigator(s)
Lynn Paxton, MD
Objective

Tested whether daily TDF/FTC (Truvada) was safe for HIV-negative sexually-active young adults in Botswana and whether it reduced risk of HIV infection.

Prevention Option(s)
PrEP
Study Design
Controlled
Randomized
Double-blind
Arms and Assigned Interventions
Description
Daily dosing
Products
TDF/FTC (Truvada)
ARMs
Experimental
Description
Daily dosing
ARMs
Placebo Comparator
Trial Sponsors
Botswana Ministry of Health, US Centers for Disease Control
Product Developers
Gilead Sciences, Inc.
March 2007
March 2011
Enrollment
1 219
18
Years
39
Years
Population
Women
Men
Sites

BOTUSA HIV Prevention Research Unit

Francistown and Gaborone
Botswana